董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| William Enright | 男 | Director | 63 | 7.23万美元 | 7.78 | 2026-03-19 |
| Vininder Singh | 男 | Chief Executive Officer and Director and Chairman | 58 | 81.80万美元 | 249.64 | 2026-03-19 |
| Jason D. Hanson | 男 | Director | 58 | 未披露 | 未持股 | 2026-03-19 |
| Jason D. Hanson | 男 | Director | 57 | 7.23万美元 | 7.28 | 2026-03-19 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Josh Blacher | 男 | Chief Financial Officer | 54 | 25.41万美元 | 0.50 | 2026-03-19 |
| Vininder Singh | 男 | Chief Executive Officer and Director and Chairman | 58 | 81.80万美元 | 249.64 | 2026-03-19 |
董事简历
中英对照 | 中文 | 英文- William Enright
-
William Enright自2019年8月以来一直担任我们的首席执行官兼董事会成员。2008年6月至2018年11月，恩莱特先生担任生物制药公司Altimmune，Inc.的首席执行官，总裁兼董事。在加入Altimmune，Inc.之前，恩赖特先生曾在Genvec，Inc.担任过多个职位，并以业务发展主管的身份离职。Enright先生拥有布法罗州立大学（SUNY at Buffalo）的生物学硕士学位和学士学位，以及约翰霍普金斯大学（Johns Hopkins University）的工商管理硕士学位。
William Enright has been a director and chair of the Compensation Committee of board since February 14, 2023. He is a seasoned biotech executive with more than thirty five years of experience in building and financing both privately held and publicly held companies and he is currently the Chief Executive Officer and a Director of Barinth Biotherapeutics plc (NASDAQ: BRNS), which he helped take public in April 2021. Prior to Barinth, Mr. Enright spent more than ten years at Altimmune (NASDAQ: ALT) as a Director, President & Chief Executive Officer, moving multiple programs into clinical testing, completing several acquisitions, and eventually taking the company public. Prior to joining Altimmune, Mr. Enright spent six years with GenVec, Inc. (acquired by Precigen) with increasing responsibilities, culminating as Head of Biness Development. Mr. Enright received a Master of Arts in Molecular Biology from SUNY at Buffalo and a Master of Science in Biness Management from Johns Hopkins University. - William Enright自2019年8月以来一直担任我们的首席执行官兼董事会成员。2008年6月至2018年11月，恩莱特先生担任生物制药公司Altimmune，Inc.的首席执行官，总裁兼董事。在加入Altimmune，Inc.之前，恩赖特先生曾在Genvec，Inc.担任过多个职位，并以业务发展主管的身份离职。Enright先生拥有布法罗州立大学（SUNY at Buffalo）的生物学硕士学位和学士学位，以及约翰霍普金斯大学（Johns Hopkins University）的工商管理硕士学位。
- William Enright has been a director and chair of the Compensation Committee of board since February 14, 2023. He is a seasoned biotech executive with more than thirty five years of experience in building and financing both privately held and publicly held companies and he is currently the Chief Executive Officer and a Director of Barinth Biotherapeutics plc (NASDAQ: BRNS), which he helped take public in April 2021. Prior to Barinth, Mr. Enright spent more than ten years at Altimmune (NASDAQ: ALT) as a Director, President & Chief Executive Officer, moving multiple programs into clinical testing, completing several acquisitions, and eventually taking the company public. Prior to joining Altimmune, Mr. Enright spent six years with GenVec, Inc. (acquired by Precigen) with increasing responsibilities, culminating as Head of Biness Development. Mr. Enright received a Master of Arts in Molecular Biology from SUNY at Buffalo and a Master of Science in Biness Management from Johns Hopkins University.
- Vininder Singh
-
Vin Singh是BullFrog AI Holdings，Inc.的Founder、董事长兼首席执行官，该公司于2017年8月成立。在过去的五年里，他从零开始建立公司，在此期间，他领导了战略，建立了一支经验丰富的领导团队，领导了BullFrog核心人工智能技术和药物资产的收购和开发，获得了第一笔收入，并筹集了大约200万美元的融资。2020年2月，他成立了BullFrog AI Holdings，Inc.，BullFrog AI Inc.成为被指定为核心知识产权持有人的全资子公司。Vin是一位连续创业者和经验丰富的高管，在生命科学和生物技术行业拥有25年的经验。他拥有丰富的创业经验，曾创立并创立过多家开创性的投资者支持的公司，包括BullFrog AI，Bullfrog Ai Holdings，Inc.提供机器学习/AI来开发药物，Next Healthcare Inc.，一家个性化诊断和成人细胞银行服务，以及MaxCyte Inc.（MXCT），一家细胞治疗公司。他还是GlobalStem Inc.和ThermoFisher Scientific的高管，领导他们的全球细胞治疗服务业务。Vin拥有罗格斯大学的电气工程学士学位、伦斯勒理工学院的生物医学工程学硕士学位和约翰霍普金斯大学的工商管理硕士学位。
Vininder Singh is the Founder, Chairman, and Chief Executive Officer of BullFrog AI Holdings, Inc. since its inception in August 2017. Over the past eight years, he has built the Company from scratch and during that time he has led strategy, built a highly experienced team of leaders, spear headed the acquisition and development of BullFrog's core AI technology and drug assets, secured the first revenue, and raised approximately $2 million in financing prior to the Company's IPO in February 2023. In February 2020, he formed BullFrog AI Holdings, Inc., and BullFrog AI Inc. became a wholly owned subsidiary designated as the holder of core intellectual property. Mr. Singh is a serial entrepreneur and experienced executive with 25 years of experience in the life sciences and biotechnology industries. He has extensive start up experience having founded and built several pioneering investor backed companies including BullFrog AI, which uses machine learning/AI to enable drug development, Next Healthcare Inc., a personalized diagnostics and adult cell banking service, and MaxCyte Inc. (NASDAQ: MXCT), a cell therapy company. He was also an executive at GlobalStem Inc. and ThermoFisher Scientific, leading their global cell therapy services business. Mr. Singh has a B.S. in Electrical Engineering from Rutgers University, an M.S. in Biomedical Engineering from Rensselaer Polytechnic Institute, and an M.B.A. from Johns Hopkins University. - Vin Singh是BullFrog AI Holdings，Inc.的Founder、董事长兼首席执行官，该公司于2017年8月成立。在过去的五年里，他从零开始建立公司，在此期间，他领导了战略，建立了一支经验丰富的领导团队，领导了BullFrog核心人工智能技术和药物资产的收购和开发，获得了第一笔收入，并筹集了大约200万美元的融资。2020年2月，他成立了BullFrog AI Holdings，Inc.，BullFrog AI Inc.成为被指定为核心知识产权持有人的全资子公司。Vin是一位连续创业者和经验丰富的高管，在生命科学和生物技术行业拥有25年的经验。他拥有丰富的创业经验，曾创立并创立过多家开创性的投资者支持的公司，包括BullFrog AI，Bullfrog Ai Holdings，Inc.提供机器学习/AI来开发药物，Next Healthcare Inc.，一家个性化诊断和成人细胞银行服务，以及MaxCyte Inc.（MXCT），一家细胞治疗公司。他还是GlobalStem Inc.和ThermoFisher Scientific的高管，领导他们的全球细胞治疗服务业务。Vin拥有罗格斯大学的电气工程学士学位、伦斯勒理工学院的生物医学工程学硕士学位和约翰霍普金斯大学的工商管理硕士学位。
- Vininder Singh is the Founder, Chairman, and Chief Executive Officer of BullFrog AI Holdings, Inc. since its inception in August 2017. Over the past eight years, he has built the Company from scratch and during that time he has led strategy, built a highly experienced team of leaders, spear headed the acquisition and development of BullFrog's core AI technology and drug assets, secured the first revenue, and raised approximately $2 million in financing prior to the Company's IPO in February 2023. In February 2020, he formed BullFrog AI Holdings, Inc., and BullFrog AI Inc. became a wholly owned subsidiary designated as the holder of core intellectual property. Mr. Singh is a serial entrepreneur and experienced executive with 25 years of experience in the life sciences and biotechnology industries. He has extensive start up experience having founded and built several pioneering investor backed companies including BullFrog AI, which uses machine learning/AI to enable drug development, Next Healthcare Inc., a personalized diagnostics and adult cell banking service, and MaxCyte Inc. (NASDAQ: MXCT), a cell therapy company. He was also an executive at GlobalStem Inc. and ThermoFisher Scientific, leading their global cell therapy services business. Mr. Singh has a B.S. in Electrical Engineering from Rutgers University, an M.S. in Biomedical Engineering from Rensselaer Polytechnic Institute, and an M.B.A. from Johns Hopkins University.
- Jason D. Hanson
-
杰森·汉森，在生效日期成为导演。他目前担任enGene，Inc.（“enGene”）总裁、首席执行官和董事，自2018年起担任该职位。在这个职位上，他为enGene公司“从头开始”建立了一个新的科学、技术和战略愿景，这家总部位于蒙特利尔、拥有十多年历史的基因治疗公司在加入公司后的六个月内以新的科学、人事和战略重新启动了公司。此外，在enGene，Hanson先生继续在新战略的基础上发展，将一项突破性的基因治疗产品从构思阶段构想成数十亿美元的临床阶段资产，组建了在研发、肿瘤学和基因治疗方面经验丰富的高级团队，并在FDA成功地领导了将BLA、临床活动扩展到一线NMIBC（非肌肉浸润性膀胱癌）的努力，有效地将潜在市场从3B美元翻倍至6B美元。此前，Hanson先生曾担任位于马萨诸塞州剑桥的生物技术公司Ohana Biosciences的总裁兼首席执行官。汉森此前曾担任NuVasive公司执行副总裁兼首席战略官，通用电气公司副总裁，通用电气公司高级管理团队成员，通用电气医疗集团是一家市值超过200亿美元的全球制药、医疗设备和医疗保健服务企业。在GE医疗集团，他负责一系列投资组合管理、企业发展、法律、合规和政府关系活动的全球业务。在加入GE医疗之前，Hanson先生曾在Valeant制药公司担任公司集团董事长兼执行副总裁，负责公司的消费者、眼科、拉丁美洲和牙科业务，以及制造和供应链、研发、监管和医疗事务团队。在此之前，他曾在Medicis制药公司担任执行副总裁兼首席运营官，领导研发和其他关键职能，并在Valeant以26亿美元收购该公司之前帮助建立了卓越的处方皮肤科和美容药品产品管道。Hanson先生在康奈尔大学获得学士学位，在杜克大学法学院获得法律学位。
Jason D. Hanson has served as a director and chair of the Nominating and Corporate Governance Committee since February 14, 2023. Mr. Hanson served as Chief Executive Officer and as a Director of enGene Inc. from July 2018 to July 2024. He also served as President of enGene Inc. from July 2018 to December 2022. Mr. Hanson effectively launched enGene from a small private company working in the GI discovery space into a clinical stage gene therapy oncology company trading on Nasdaq, with a massively differentiated lead product to treat bladder cancer, implementing a new scientific, technical and strategic vision for the Company. From Augt 2016 to November 2017, Mr. Hanson served as President and Chief Executive Officer of Ohana Biosciences, a biotechnology company based in Cambridge, MA, and as a member of the Ohana Board of Directors and consultant to Ohana from November 2017 to June 2018. Mr. Hanson previoly served as Executive Vice President and Chief Strategy Officer for NuVasive, Inc. from November 2015 to Augt 2016. Mr. Hanson served as Corporate Vice President of General Electric Company and member of the senior executive team of GE Healthcare, a global pharmaceutical, medical device and healthcare services biness from May 2014 to October 2015. In January 2013, Mr. Hanson served as Company Group Chairman and Executive Vice President of Valeant Pharmaceuticals International, Inc. (now Bach Health Companies Inc.). Previoly, he served in vario roles at Medicis Pharmaceutical Corporation, including as Executive Vice President and Chief Operating Officer beten July 2006 and December 2012. Mr. Hanson also served in numero roles at GE Healthcare, including General Counsel roles, from April 1999 to July 2006. Mr. Hanson holds a B.S. from Cornell University and a J.D. from Duke University School of Law. - 杰森·汉森，在生效日期成为导演。他目前担任enGene，Inc.（“enGene”）总裁、首席执行官和董事，自2018年起担任该职位。在这个职位上，他为enGene公司“从头开始”建立了一个新的科学、技术和战略愿景，这家总部位于蒙特利尔、拥有十多年历史的基因治疗公司在加入公司后的六个月内以新的科学、人事和战略重新启动了公司。此外，在enGene，Hanson先生继续在新战略的基础上发展，将一项突破性的基因治疗产品从构思阶段构想成数十亿美元的临床阶段资产，组建了在研发、肿瘤学和基因治疗方面经验丰富的高级团队，并在FDA成功地领导了将BLA、临床活动扩展到一线NMIBC（非肌肉浸润性膀胱癌）的努力，有效地将潜在市场从3B美元翻倍至6B美元。此前，Hanson先生曾担任位于马萨诸塞州剑桥的生物技术公司Ohana Biosciences的总裁兼首席执行官。汉森此前曾担任NuVasive公司执行副总裁兼首席战略官，通用电气公司副总裁，通用电气公司高级管理团队成员，通用电气医疗集团是一家市值超过200亿美元的全球制药、医疗设备和医疗保健服务企业。在GE医疗集团，他负责一系列投资组合管理、企业发展、法律、合规和政府关系活动的全球业务。在加入GE医疗之前，Hanson先生曾在Valeant制药公司担任公司集团董事长兼执行副总裁，负责公司的消费者、眼科、拉丁美洲和牙科业务，以及制造和供应链、研发、监管和医疗事务团队。在此之前，他曾在Medicis制药公司担任执行副总裁兼首席运营官，领导研发和其他关键职能，并在Valeant以26亿美元收购该公司之前帮助建立了卓越的处方皮肤科和美容药品产品管道。Hanson先生在康奈尔大学获得学士学位，在杜克大学法学院获得法律学位。
- Jason D. Hanson has served as a director and chair of the Nominating and Corporate Governance Committee since February 14, 2023. Mr. Hanson served as Chief Executive Officer and as a Director of enGene Inc. from July 2018 to July 2024. He also served as President of enGene Inc. from July 2018 to December 2022. Mr. Hanson effectively launched enGene from a small private company working in the GI discovery space into a clinical stage gene therapy oncology company trading on Nasdaq, with a massively differentiated lead product to treat bladder cancer, implementing a new scientific, technical and strategic vision for the Company. From Augt 2016 to November 2017, Mr. Hanson served as President and Chief Executive Officer of Ohana Biosciences, a biotechnology company based in Cambridge, MA, and as a member of the Ohana Board of Directors and consultant to Ohana from November 2017 to June 2018. Mr. Hanson previoly served as Executive Vice President and Chief Strategy Officer for NuVasive, Inc. from November 2015 to Augt 2016. Mr. Hanson served as Corporate Vice President of General Electric Company and member of the senior executive team of GE Healthcare, a global pharmaceutical, medical device and healthcare services biness from May 2014 to October 2015. In January 2013, Mr. Hanson served as Company Group Chairman and Executive Vice President of Valeant Pharmaceuticals International, Inc. (now Bach Health Companies Inc.). Previoly, he served in vario roles at Medicis Pharmaceutical Corporation, including as Executive Vice President and Chief Operating Officer beten July 2006 and December 2012. Mr. Hanson also served in numero roles at GE Healthcare, including General Counsel roles, from April 1999 to July 2006. Mr. Hanson holds a B.S. from Cornell University and a J.D. from Duke University School of Law.
- Jason D. Hanson
-
Jason D. Hanson，自2015年11月起担任战略、企业发展和总法律顾问执行副总裁，负责领导NuVasive的企业发展和并购战略，以及与公司有关的所有法律事务，包括公司和战略交易、诉讼和风险管理，以及其他业务事务。他曾担任GE Healthcare的公司副总裁、首席风险官和副总裁、总法律顾问(2014年5月以来)，负责法律、合规、政府关系、企业风险管理和各种关键企业发展活动的全球业务。在加入GE Healthcare之前，他曾担任Valeant Pharmaceuticals的公司集团董事长兼执行副总裁(2012年至2013年)，负责消费者、眼科、拉丁美洲和牙科业务，以及制造和供应链、研发、监管和医疗事务团队。他此前在Medicis Pharmaceutical Corporation工作了7年，自2010年起担任执行副总裁兼首席运营官。他于2006年加入Medicis，并被任命为执行副总裁、总法律顾问和公司秘书。2004年至2006年，他担任GE医疗技术公司的总法律顾问，负责全球法律事务;2001年至2004年，他担任GE医疗系统公司美洲地区的总法律顾问。他于1999年首次加入GE，担任GE Medical Systems的诉讼和合规高级法律顾问。他的职业生涯始于华盛顿特区的Arnold & Porter，然后在华盛顿特区的美国司法部反垄断部门担任检察官和审判律师。他持有Cornell University的学士学位和Duke University School of Law的法学博士学位。
Jason D. Hanson has served as Nuvasive, Inc. Executive Vice President, Strategy, Corporate Development and General Counsel since November 2015 and is responsible for leading NuVasive's corporate development and mergers and acquisitions strategy, in addition to all legal matters pertaining to the Company, including corporate and strategic transactions, litigation and risk management, among other business matters. Mr. Hanson previously served as Corporate Vice President, Chief Risk Officer and Vice President, General Counsel of GE Healthcare since May 2014 where he had global business responsibility for legal, compliance, government relations, enterprise risk management and various key corporate development activities. Prior to joining GE Healthcare, he served as Company Group Chairman and Executive Vice President at Valeant Pharmaceuticals from 2012 to 2013 with responsibility for the Consumer, Ophthalmology, Latin American and Dental businesses, as well as the manufacturing and supply chain, R&D, regulatory and medical affairs teams. Mr. Hanson previously spent seven years at Medicis Pharmaceutical Corporation where he served as Executive Vice President and Chief Operating Officer since 2010. He joined Medicis in 2006 and was appointed to the position of Executive Vice President, General Counsel and Corporate Secretary. Between 2004 and 2006 Mr. Hanson served as General Counsel for GE Healthcare Technologies where he was responsible for global legal affairs, and from 2001 to 2004 he was General Counsel for the Americas region at GE Medical Systems. Mr. Hanson first joined GE in 1999 serving as Senior Counsel for Litigation and Compliance for GE Medical Systems. He began his career with Arnold & Porter in Washington, D.C. and then went on to serve with the United States Department of Justice, Antitrust Division in Washington D.C. as a prosecutor and trial attorney.Mr. Hanson holds a B.S. from Cornell University and a J.D. from Duke University School of Law. - Jason D. Hanson，自2015年11月起担任战略、企业发展和总法律顾问执行副总裁，负责领导NuVasive的企业发展和并购战略，以及与公司有关的所有法律事务，包括公司和战略交易、诉讼和风险管理，以及其他业务事务。他曾担任GE Healthcare的公司副总裁、首席风险官和副总裁、总法律顾问(2014年5月以来)，负责法律、合规、政府关系、企业风险管理和各种关键企业发展活动的全球业务。在加入GE Healthcare之前，他曾担任Valeant Pharmaceuticals的公司集团董事长兼执行副总裁(2012年至2013年)，负责消费者、眼科、拉丁美洲和牙科业务，以及制造和供应链、研发、监管和医疗事务团队。他此前在Medicis Pharmaceutical Corporation工作了7年，自2010年起担任执行副总裁兼首席运营官。他于2006年加入Medicis，并被任命为执行副总裁、总法律顾问和公司秘书。2004年至2006年，他担任GE医疗技术公司的总法律顾问，负责全球法律事务;2001年至2004年，他担任GE医疗系统公司美洲地区的总法律顾问。他于1999年首次加入GE，担任GE Medical Systems的诉讼和合规高级法律顾问。他的职业生涯始于华盛顿特区的Arnold & Porter，然后在华盛顿特区的美国司法部反垄断部门担任检察官和审判律师。他持有Cornell University的学士学位和Duke University School of Law的法学博士学位。
- Jason D. Hanson has served as Nuvasive, Inc. Executive Vice President, Strategy, Corporate Development and General Counsel since November 2015 and is responsible for leading NuVasive's corporate development and mergers and acquisitions strategy, in addition to all legal matters pertaining to the Company, including corporate and strategic transactions, litigation and risk management, among other business matters. Mr. Hanson previously served as Corporate Vice President, Chief Risk Officer and Vice President, General Counsel of GE Healthcare since May 2014 where he had global business responsibility for legal, compliance, government relations, enterprise risk management and various key corporate development activities. Prior to joining GE Healthcare, he served as Company Group Chairman and Executive Vice President at Valeant Pharmaceuticals from 2012 to 2013 with responsibility for the Consumer, Ophthalmology, Latin American and Dental businesses, as well as the manufacturing and supply chain, R&D, regulatory and medical affairs teams. Mr. Hanson previously spent seven years at Medicis Pharmaceutical Corporation where he served as Executive Vice President and Chief Operating Officer since 2010. He joined Medicis in 2006 and was appointed to the position of Executive Vice President, General Counsel and Corporate Secretary. Between 2004 and 2006 Mr. Hanson served as General Counsel for GE Healthcare Technologies where he was responsible for global legal affairs, and from 2001 to 2004 he was General Counsel for the Americas region at GE Medical Systems. Mr. Hanson first joined GE in 1999 serving as Senior Counsel for Litigation and Compliance for GE Medical Systems. He began his career with Arnold & Porter in Washington, D.C. and then went on to serve with the United States Department of Justice, Antitrust Division in Washington D.C. as a prosecutor and trial attorney.Mr. Hanson holds a B.S. from Cornell University and a J.D. from Duke University School of Law.
高管简历
中英对照 | 中文 | 英文- Josh Blacher
Josh Blacher，公司首席财务官，自2015年1月起担任该职位。在此之前，Blacher于2014年10月加入公司担任企业开发高级主管。Blacher在生物技术相关业务开发、运营和投资领域有着14年多的经验，在资本市场领域有着14年多的经验。加入公司之前，Blacher从2008年到2011年担任Teva Innovative Ventures（Teva Pharmaceuticals的早期和中期发展阶段投资和营业执照）业务开发主管。任职期间，Blacher帮助建立并管理Teva在生物技术公司的200个股权投资组合，涵盖多领域发展阶段的公司，从预临床到阶段3项目以及多个疗法领域。之前，从1995年到2005年Blacher在Deutsche Asset Management担任投资组合经理职位；在Morgan Stanley担任股权研究职位；在Lehman Brothers的并购小组工作。Blacher于2001年获得Columbia Business School 金融工商管理硕士学位；1995年获得Yeshiva University经济学文学学士学位。
Josh Blacher has been the Chief Financial Officer of BullFrog AI Holdings, Inc. since December 2024. Mr. Blacher has served as an employee of Danforth Advisors since September 2022, where he has worked as a Chief Financial Officer in a consulting capacity for a number of life sciences companies as ll as Managing Partner of Columb Circle Capital LLC since Augt 2019. In his capacity as a consultant of Danforth, he has served as Chief Financial Officer of Predictive Oncology since September 2023 as ll as Axe Compute, among others. During his tenure at Columb Circle Capital, Mr. Blacher has served as chief financial officer at several public and private companies. Prior to his tenure at Columb Circle Capital, Mr. Blacher served as Chief Biness Officer at InMed Pharmaceuticals (Nasdaq: INM) from April 2018 to Augt 2019, as Chief Financial Officer of Therapix Biosciences (Nasdaq: TRPX) from April 2017 to April 2018, and as Chief Financial Officer at Galmed Pharmaceuticals (Nasdaq: GLMD) from October 2014 to March 2017. Earlier in his career, Mr. Blacher served in senior capacities at Teva Pharmaceuticals, Deutsche Asset Management and Morgan Stanley. Mr. Blacher holds a Bachelor of Arts from Yeshiva University and an M.B.A. from Columbia Biness School.- Josh Blacher，公司首席财务官，自2015年1月起担任该职位。在此之前，Blacher于2014年10月加入公司担任企业开发高级主管。Blacher在生物技术相关业务开发、运营和投资领域有着14年多的经验，在资本市场领域有着14年多的经验。加入公司之前，Blacher从2008年到2011年担任Teva Innovative Ventures（Teva Pharmaceuticals的早期和中期发展阶段投资和营业执照）业务开发主管。任职期间，Blacher帮助建立并管理Teva在生物技术公司的200个股权投资组合，涵盖多领域发展阶段的公司，从预临床到阶段3项目以及多个疗法领域。之前，从1995年到2005年Blacher在Deutsche Asset Management担任投资组合经理职位；在Morgan Stanley担任股权研究职位；在Lehman Brothers的并购小组工作。Blacher于2001年获得Columbia Business School 金融工商管理硕士学位；1995年获得Yeshiva University经济学文学学士学位。
- Josh Blacher has been the Chief Financial Officer of BullFrog AI Holdings, Inc. since December 2024. Mr. Blacher has served as an employee of Danforth Advisors since September 2022, where he has worked as a Chief Financial Officer in a consulting capacity for a number of life sciences companies as ll as Managing Partner of Columb Circle Capital LLC since Augt 2019. In his capacity as a consultant of Danforth, he has served as Chief Financial Officer of Predictive Oncology since September 2023 as ll as Axe Compute, among others. During his tenure at Columb Circle Capital, Mr. Blacher has served as chief financial officer at several public and private companies. Prior to his tenure at Columb Circle Capital, Mr. Blacher served as Chief Biness Officer at InMed Pharmaceuticals (Nasdaq: INM) from April 2018 to Augt 2019, as Chief Financial Officer of Therapix Biosciences (Nasdaq: TRPX) from April 2017 to April 2018, and as Chief Financial Officer at Galmed Pharmaceuticals (Nasdaq: GLMD) from October 2014 to March 2017. Earlier in his career, Mr. Blacher served in senior capacities at Teva Pharmaceuticals, Deutsche Asset Management and Morgan Stanley. Mr. Blacher holds a Bachelor of Arts from Yeshiva University and an M.B.A. from Columbia Biness School.
- Vininder Singh
Vin Singh是BullFrog AI Holdings，Inc.的Founder、董事长兼首席执行官，该公司于2017年8月成立。在过去的五年里，他从零开始建立公司，在此期间，他领导了战略，建立了一支经验丰富的领导团队，领导了BullFrog核心人工智能技术和药物资产的收购和开发，获得了第一笔收入，并筹集了大约200万美元的融资。2020年2月，他成立了BullFrog AI Holdings，Inc.，BullFrog AI Inc.成为被指定为核心知识产权持有人的全资子公司。Vin是一位连续创业者和经验丰富的高管，在生命科学和生物技术行业拥有25年的经验。他拥有丰富的创业经验，曾创立并创立过多家开创性的投资者支持的公司，包括BullFrog AI，Bullfrog Ai Holdings，Inc.提供机器学习/AI来开发药物，Next Healthcare Inc.，一家个性化诊断和成人细胞银行服务，以及MaxCyte Inc.（MXCT），一家细胞治疗公司。他还是GlobalStem Inc.和ThermoFisher Scientific的高管，领导他们的全球细胞治疗服务业务。Vin拥有罗格斯大学的电气工程学士学位、伦斯勒理工学院的生物医学工程学硕士学位和约翰霍普金斯大学的工商管理硕士学位。
Vininder Singh is the Founder, Chairman, and Chief Executive Officer of BullFrog AI Holdings, Inc. since its inception in August 2017. Over the past eight years, he has built the Company from scratch and during that time he has led strategy, built a highly experienced team of leaders, spear headed the acquisition and development of BullFrog's core AI technology and drug assets, secured the first revenue, and raised approximately $2 million in financing prior to the Company's IPO in February 2023. In February 2020, he formed BullFrog AI Holdings, Inc., and BullFrog AI Inc. became a wholly owned subsidiary designated as the holder of core intellectual property. Mr. Singh is a serial entrepreneur and experienced executive with 25 years of experience in the life sciences and biotechnology industries. He has extensive start up experience having founded and built several pioneering investor backed companies including BullFrog AI, which uses machine learning/AI to enable drug development, Next Healthcare Inc., a personalized diagnostics and adult cell banking service, and MaxCyte Inc. (NASDAQ: MXCT), a cell therapy company. He was also an executive at GlobalStem Inc. and ThermoFisher Scientific, leading their global cell therapy services business. Mr. Singh has a B.S. in Electrical Engineering from Rutgers University, an M.S. in Biomedical Engineering from Rensselaer Polytechnic Institute, and an M.B.A. from Johns Hopkins University.- Vin Singh是BullFrog AI Holdings，Inc.的Founder、董事长兼首席执行官，该公司于2017年8月成立。在过去的五年里，他从零开始建立公司，在此期间，他领导了战略，建立了一支经验丰富的领导团队，领导了BullFrog核心人工智能技术和药物资产的收购和开发，获得了第一笔收入，并筹集了大约200万美元的融资。2020年2月，他成立了BullFrog AI Holdings，Inc.，BullFrog AI Inc.成为被指定为核心知识产权持有人的全资子公司。Vin是一位连续创业者和经验丰富的高管，在生命科学和生物技术行业拥有25年的经验。他拥有丰富的创业经验，曾创立并创立过多家开创性的投资者支持的公司，包括BullFrog AI，Bullfrog Ai Holdings，Inc.提供机器学习/AI来开发药物，Next Healthcare Inc.，一家个性化诊断和成人细胞银行服务，以及MaxCyte Inc.（MXCT），一家细胞治疗公司。他还是GlobalStem Inc.和ThermoFisher Scientific的高管，领导他们的全球细胞治疗服务业务。Vin拥有罗格斯大学的电气工程学士学位、伦斯勒理工学院的生物医学工程学硕士学位和约翰霍普金斯大学的工商管理硕士学位。
- Vininder Singh is the Founder, Chairman, and Chief Executive Officer of BullFrog AI Holdings, Inc. since its inception in August 2017. Over the past eight years, he has built the Company from scratch and during that time he has led strategy, built a highly experienced team of leaders, spear headed the acquisition and development of BullFrog's core AI technology and drug assets, secured the first revenue, and raised approximately $2 million in financing prior to the Company's IPO in February 2023. In February 2020, he formed BullFrog AI Holdings, Inc., and BullFrog AI Inc. became a wholly owned subsidiary designated as the holder of core intellectual property. Mr. Singh is a serial entrepreneur and experienced executive with 25 years of experience in the life sciences and biotechnology industries. He has extensive start up experience having founded and built several pioneering investor backed companies including BullFrog AI, which uses machine learning/AI to enable drug development, Next Healthcare Inc., a personalized diagnostics and adult cell banking service, and MaxCyte Inc. (NASDAQ: MXCT), a cell therapy company. He was also an executive at GlobalStem Inc. and ThermoFisher Scientific, leading their global cell therapy services business. Mr. Singh has a B.S. in Electrical Engineering from Rutgers University, an M.S. in Biomedical Engineering from Rensselaer Polytechnic Institute, and an M.B.A. from Johns Hopkins University.